Sun Pharma Advanced Research Company
Market cap ₹6,170 Cr
- P/E
- 3.77
- Day range
- ₹188.00 – ₹194.45
- 52-week range
- ₹108.00 – ₹289.00
- Volume
- 6.10 L
- Open
- ₹192.64
- Prev close
- ₹193.24
Latest results · Q2 FY27(consolidated)Revenue ₹30 Cr+282.1%Profit ₹-24 CrMargin -81.2%YoY vs the same quarter last year
1 red flag to read up on
- medium
Material exchange filing
Clarification sought from Sun Pharma Advanced Research Company Ltd · 11 Nov 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
SPARC in NSE indices and F&O
Research profile
Composite 53 / 100Factor percentiles
Derived metrics
- Earn. yield
- 26.5%
- Graham no.
- ₹223.57
- vs Graham
- +17.6%
- ROE ÷ P/B
- 63.7%
- 12-1 mom.
- +43.6%
- Return / vol
- 0.82
- Magic Formula
- #1
- Piotroski
- 4/6
- FCF yield
- -4.2%
Appears in 15 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Sun Pharma Advanced Research CompanySPARC | ₹6,170 Cr | 3.77 | 4.35 | 277.1% | 164.0% | -152.0% | 0.00 | +275.0% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 1h agoHeadlines about Sun Pharma Advanced Research Company from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 3.8
- Price / Book
- 4.28
- ROE (FY26)
- 277.1%
- ROCE (latest year)
- 164%
- Dividend yield
- 0.00%
Moving averages (NSE)
- 20-day
- ₹188.42
- Price above
- 50-day
- ₹192.66
- Price below
- 200-day
- ₹181.45
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- FII
- DII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14 | 17 | 17 | 13 | 15 | 27 | 10 | 8 | 8 | 1,853 | 40 | 30 |
| YoY Sales growth | — | -65 | -30 | -39 | — | — | -43 | -39 | -43 | — | — | — |
| Expenses | 116 | 122 | 110 | 116 | 89 | 80 | 62 | 74 | 65 | 80 | 74 | 76 |
| Operating Profit | -103 | -106 | -93 | -103 | -74 | -53 | -52 | -66 | -57 | 1,773 | -34 | -46 |
| OPM % | -740% | -639% | -555% | -800% | -494% | -196% | -540% | -836% | -670% | 96% | -85% | -152% |
| Other Income | 6 | 4 | 2 | 0 | 0 | 0 | 9 | 0 | -12 | 2 | 24 | 24 |
| Interest | 0 | 1 | 1 | 1 | 3 | 5 | 6 | 8 | 9 | 12 | 8 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
| Profit before tax | -100 | -105 | -96 | -107 | -79 | -61 | -52 | -76 | -80 | 1,761 | -21 | -24 |
| Tax % | 0% | 0% | 0% | 0% | 0% | -1% | 0% | 0% | 0% | 0% | 1% | 0% |
| Net Profit | -100 | -106 | -96 | -107 | -80 | -60 | -52 | -76 | -80 | 1,761 | -21 | -24 |
| EPS in Rs | ₹-3.07 | ₹-3.26 | ₹-2.96 | ₹-3.31 | ₹-2.45 | ₹-1.84 | ₹-1.60 | ₹-2.34 | ₹-2.48 | ₹54.27 | ₹-0.64 | ₹-0.75 |
From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-23 days since Mar 2021 (S)
0 days since Mar 2021 (S)
-23 days since Mar 2021 (S)
+483 days since Mar 2021 (S)
Strengths, risks & growth
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products. [1]
Strengths
- Company has reduced debt.
- Company is almost debt free.
Risks
- Stock is trading at 4.35 times its book value
- Working capital days have increased from -768 days to 215 days
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- —
- 3 Years
- +99%
- TTM
- +3141%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- —
- 3 Years
- +108%
- TTM
- +717%
Stock Price CAGR
- 10 Years
- -5%
- 5 Years
- -6%
- 3 Years
- -8%
- 1 Year
- +47%
Return on Equity
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- Last Year
- +279%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 65.67% | 65.67% | 65.68% | 65.68% | 0.00 pp |
| FII | 2.04% | 2.04% | 3.90% | 3.74% | -0.16 pp |
| DII | 0.78% | 0.88% | 0.09% | 0.11% | +0.02 pp |
| Public | 31.51% | 31.41% | 30.34% | 30.48% | +0.14 pp |
Filed with NSE for Sept 2026: promoters 65.67%, public 34.33%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 0.10% (+0.02 pp)- Promoters65.7%
- Foreign institutions3.8%
- Mutual funds0.1%
- Insurance0.0%
- Other domestic institutions0.0%
- Retail14.5%
- Others15.9%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Motilal Oswal Nifty Microcap 250 Index Fund | 0.07% | 0.20% | -0.01 pp |
| Samco Multi Cap Fund | 0.01% | 0.30% | -0.05 pp |
| Groww Nifty Total Market Index Fund | 0.00% | 0.01% | -0.00 pp |
| Bandhan BSE Healthcare Index Fund | 0.00% | 0.10% | -0.02 pp |
| Aditya Birla SL BSE Total Market Index Fund | 0.00% | 0.01% | +0.01 pp |
Scorecard
- Performance
- Avg
- Valuation
- Avg
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 54.5%
- Downside volatility
- 41.7%
- Worst 5% of days
- 4.6%
- Average of that tail
- 6.0%
- Max drawdown (1Y)
- 38.1%
- Below its peak
- 31.5%
Against the market
- Beta vs Nifty 50
- 1.65
- Correlation
- 0.41
- Relative strength (3M)
- -7.5%
- ATR (14)
- 5.0%
Return
- Return 1M
- +0.8%
- Return 3M
- -3.7%
- Return 6M
- +17.2%
- Return 1Y
- +44.7%
- vs 200-day average
- +4.8%
Momentum
- RSI (14)
- 47.9
- MACD histogram
- 0.95
- Stochastic %K
- 39.9
- ADX (14)
- 18.1
- +DI / −DI
- 26.0 / 24.3
- Money flow index
- 83.4
Participation
- Delivery (20d avg)
- 34.8%
- vs its 60-day baseline
- -4.0 pts
- Volume vs 20-day
- -0.3σ
- Close vs day's VWAP
- -0.0%
- 52-week position
- 48 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
4 of 6 tested
- Return on assets positive — failed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — failed
- Free cash flow
- -₹263 Cr
- FCF yield
- -4.2%
- Cash conversion
- -0.15
- Accruals ratio
- 0.825
- Net debt
- -₹0 Cr
- Net debt / equity
- -0.00
- EV / sales
- 3.25
- Capex intensity
- 1.3%
- Revenue CAGR
- 6.8%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- otherNot available — not reported in this filing
Annual General Meeting
21 Sept 2021ex-date - otherNot available — not reported in this filing
Annual General Meeting
22 Sept 2020ex-date - otherNot available — not reported in this filing
Annual General Meeting
18 Jul 2019ex-date - otherNot available — not reported in this filing
Annual General Meeting
19 Jul 2018ex-date - otherNot available — not reported in this filing
Annual General Meeting
27 Jul 2017ex-date - otherNot available — not reported in this filing
Extraordinary General Meeting
25 May 2017ex-date - otherNot available — not reported in this filing
Annual General Meeting
21 Jul 2016ex-date - rightsNot available — not reported in this filing
Rights 5: 116 At Premium Rs 244/- Per Share
16 Mar 2016ex-date - otherNot available — not reported in this filing
Annual General Meeting
23 Jul 2015ex-date - otherNot available — not reported in this filing
Annual General Meeting
24 Jul 2014ex-date - otherNot available — not reported in this filing
Annual General Meeting
24 Jul 2013ex-date - rightsNot available — not reported in this filing
Rights 1: 7@ Premium Rs 66 Per Share
23 Aug 2012ex-date - otherNot available — not reported in this filing
Annual General Meeting
28 Jul 2011ex-date - otherNot available — not reported in this filing
Annual General Meeting
16 Jul 2010ex-date - otherNot available — not reported in this filing
Annual General Meeting
21 Aug 2009ex-date - otherNot available — not reported in this filing
Annual General Meeting
25 Aug 2008ex-date - otherNot available — not reported in this filing
Agm
28 Aug 2007ex-date
Company announcements
Receipt of No- Objection Letters from the Stock Exchanges for Reclassification of Promoter Group
Response of Clarification sought from BSE Limited
The Exchange has sought clarification from Sun Pharma Advanced Research Company Ltd on November 11, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.
Newspaper Advertisement for Publication of Financial Results
Monitoring Agency Report for the quarter ended September 30, 2026
Financial Results for the quarter and half year ended September 30, 2026
Sun Pharma Advanced Research Company Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve unaudited ....
Confirmation Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
Update on Litigation under regulation 30 of SEBI (LODR), 2015
Intimation regarding Closure of Trading Window
Filing of Application for Reclassification with Stock Exchanges
Newspaper Advertisement for Publication of Financials
Outcome of 21st Annual General Meeting of Sun Pharma Advanced Research Company Limited held on August 10, 2026
Monitoring Agency Report for the Quarter ended June 30, 2026
Financial Results
Filed with BSE (scrip 532872); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Buybacks, open offers & rights issues
- Rights issue
Sun Pharma Advanced Research Company Limited
22 Mar 2016Read on SEBI - Rights issue
Sun Pharma Advanced Research Company Limited.
21 Sept 2015Read on SEBI - Rights issue
Sun Pharma Advanced Research Company Limited
16 Aug 2012Read on SEBI - Rights issue
Sun Pharma Advanced Research Company Limited
2 Feb 2012Read on SEBI
Documents
Annual reports
Earnings calls
- Jan 2026TranscriptSlides
- Dec 2024TranscriptSlides
- Apr 2024TranscriptRecording
- Jan 2024Transcript
- Jan 2024TranscriptSlides
- Jan 2024Slides
Credit ratings
- Rating update · 6 Feb from smera
- Rating update · 5 Mar 2025 from smera
- Rating update · 6 Dec 2023 from smera
- Rating update · 7 Sep 2022 from smera
- Rating update · 21 Jun 2021 from smera
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Sun Pharma Advanced Research Company: common questions
Answered from the figures on this page.